Novel therapies based on mechanisms of HIV-1 cell entry.
Kilby
J Michael
JM
Department of Medicine, University of Alabama, Birmingham, USA. mkilby@uab.edu
Eron
Joseph J
JJ
D000595:Amino Acid Sequence; D015704:CD4 Antigens / Q000187:drug effects; D015496:CD4-Positive T-Lymphocytes / Q000502:physiology; D000077560:Enfuvirtide; D015699:HIV Envelope Protein gp120 / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D015700:HIV Envelope Protein gp41 / Q000009:adverse effects / Q000627:therapeutic use; D023581:HIV Fusion Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D017320:HIV Protease Inhibitors; D015497:HIV-1 / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D008561:Membrane Fusion / Q000187:drug effects* / Q000502:physiology*; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000009:adverse effects / Q000627:therapeutic use; D019707:Receptors, Chemokine / Q000187:drug effects* / Q000378:metabolism; D018894:Reverse Transcriptase Inhibitors / Q000378:metabolism; D014759:Viral Envelope Proteins / Q000737:chemistry / Q000378:metabolism
D015704:CD4 Antigens; D015699:HIV Envelope Protein gp120; D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D017320:HIV Protease Inhibitors; D010446:Peptide Fragments; D019707:Receptors, Chemokine; D018894:Reverse Transcriptase Inhibitors; D014759:Viral Envelope Proteins; C474741:peptide T1249; D000077560:Enfuvirtide